



Physician

Specialties:

Hematology
Medical Oncology

Board Certifications:

Medical Oncology
Hematology
Internal Medicine

Texas Oncology-San Marcos

1308 Wonder World Dr.
San Marcos, TX 78666
T: 512-396-5199

Texas Oncology-South Austin

4101 James Casey St.,
Suite 100
Austin, TX 78745
T: 512-447-2202

**Metro Area: Austin
Clinical Trials in Austin**

Education

- **Fellowship in Hematology/Medical Oncology**
Cornell Medical Center, New York, NY
- **Chief Fellow in Hematology/Medical Oncology**
Cornell Medical Center, New York, NY
- **Chief Resident in Internal Medicine**
St Luke's/Roosevelt Hospital Center, New York, NY
- **Internship & Residency in Internal Medicine**
St Luke's/Roosevelt Hospital Center, New York, NY
- **Rotating Internship**
Dr. Manuel Gea Gonzales General Hospital, Mexico City, MX
- **Medical Degree**
Universidad La Salle Medical School, Mexico City, MX

Medical Practice

- Physician, Hematology/Medical Oncology, Texas Oncology Central Austin, Austin, Texas (2008-Present)
- Physician, Hematology/Medical Oncology, Southwest Regional Cancer Center, Austin, Texas (2006-2008)
- Physician, Hematology/Medical Oncology, Ochsner Clinic Foundation, New Orleans, Louisiana (1998-2006)
- Louisiana Blood Bank, New Orleans, Louisiana (1989-1991)
- Social Services—Research, National Cancer Institute, Mexico City, MX (1987-1989)

Accolades & Memberships

- "Best Doctors in America," Best Doctors Database
- "Top Doctors in New Orleans," New Orleans Magazine
- Community of Caring Award, Ochsner Clinic Foundation New Orleans, Louisiana
- Texas Medical Association
- Travis County Medical Society
- American College of Physicians
- American Medical Association
- American Society of Clinical Oncology
- American Society of Hematology
- New York State Society of Internal Medicine
- North Central Cancer Treatment Group
- Eastern Cooperative Oncology Group
- Radiation Treatment Oncology Group
- National Surgical Adjuvant Breast & Bowel Project

Research Interest

- A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Drug A With and Without Drug B in the First-line Treatment of Subject With Metastatic Colorectal Cancer
- Phase II, Multicenter, Open-Label, Non-Randomized Study of Intravenous Drug A Q 3 Weeks in Patients with Metastatic Breast Cancer Progressing After Therapy with Drug B, Drug C, and Drug D
- A Phase III Trial of Novel Drug A Plus Drug B versus Drug B Alone in Patients with Advanced Breast Cancer Previously Treated with or Resistant to a Drug C and who are Drug D Resistant
- Randomized Trial of Plus Chemotherapies in Metastatic Breast Cancer in 1st and 2nd Line Patients
- A Randomized, Open-label Trial Comparing Drug A and Drug B Drug-based Treatment Regimens for the First-line Treatment of Metastatic Colorectal Cancer (mCRC)
- A Phase III, Multicenter, Placebo-Controlled, Double-Blind, randomized Clinical Trial To Evaluate The Efficacy Of Drug A In Combination With Drug B Compared With Drug A Alone For Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure Of Standard First-Line Chemotherapy
- Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Drug A 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Drug A Drug 0.25

mg IV for the Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting in Patients with Cancer.

- A Phase IV Open Label Trial Using Drug A for Re-treatment of Multiple Myeloma Patients Following an Initial Response to Drug B
- A Randomized Phase II Comparative Study of Drug A and Drug B Second-Line Therapy for Patients with Resistant and Refractory Small Cell Lung Cancer
- A Dual-cohort, Perspective, Observational Study of Unresectable Stage IIIB/IV Non-small Cell Lung Cancer Patients with and without Bone Metastasis

Publications

- **Active Immunotherapy with Mitumprotirnut-T (FavId®, Id-KLH) Following Rituxirab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL); Progression Free Survival (PFS) at 4-Years Follow Up**
Blood, 2007
- **Continued Late Conversion to Complete Remission (*CR/Cm) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by MitumprotiMut-T (Id-KLH, FavID®) Active Immunotherapy**
Blood, 2007
- **Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement and Disease Progression in Follicular Lymphoma Patients**
Blood, 2006
- **Intravascular B-cell Lymphoma**
Community Oncology, 2005
- **Efficacy and Safety Analysis of Epoetin Alfa in Patients with Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial**
Journal of Clinical Oncology, 2005